To investigate whether this variation in IRF2 expression potentially had functional consequences, we analyzed the TCGA RNAseq database to determine whether cancer cases that downregulated IRF2 transcripts levels had corresponding reductions in the expression of MHC I pathway genes (μ2M, ERAP1/2, HLA-ABC, PDIA3, PSMB8–10 PSME1, TAP1/2, TAPBP and TABPL), as well as a few other IRF2-regulated genes (CASP7, CD274 and GSDMD). The gene discussed is IRF2; the disease is cancer.